Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-502
- Development stage
- Preclinical
- Lead developer
- Kuur Therapeutics
- Modality
- Small Molecules
01
Overview
CAR-502 is an investigational drug candidate being developed by Carmel Biosciences. It is currently in the IND-enabling stage of development, following FDA Pre-IND approval. Carmel Biosciences specializes in the 505(b)(2) regulatory pathway, which involves creating new formulations or delivery methods for previously approved drugs to improve their clinical profile, such as bioavailability and safety. While the specific active pharmaceutical ingredient and biological target for CAR-502 have not been publicly disclosed, the company's pipeline is primarily focused on addressing unmet needs in cardiovascular and metabolic health.
Beyond the preview
Go deeper on CAR-502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-502.